XFOR Earnings X4 Pharmaceuticals, Inc
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–21 of 21
| Q2 2026 | 2026-06-30 | -0.29 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.16 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -1.87 | 2026-03-17 | 10-K |
| Q3 2025 | 2025-09-30 | -2.87 | 2025-11-05 | 10-Q |
| Q2 2026 | 2025-06-30 | -3.59 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | 0.04 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -5.59 | 2026-03-17 | 10-K |
| Q3 2025 | 2024-09-30 | 0.35 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | 5.85 | 2025-08-08 | 10-Q |
| Q1 2025 | 2024-03-31 | -7.77 | 2025-05-01 | 10-Q |
| FY 2025 | 2023-12-31 | -17.07 | 2026-03-17 | 10-K |
| Q3 2024 | 2023-09-30 | -0.48 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.51 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.16 | 2024-05-07 | 10-Q |
| FY 2024 | 2022-12-31 | -1.52 | 2025-03-26 | 10-K |
| Q3 2023 | 2022-09-30 | -1.32 | 2023-11-09 | 10-Q |
| Q3 2023 | 2022-06-30 | -1.31 | 2023-08-10 | 10-Q |
| Q3 2022 | 2022-03-31 | -0.72 | 2023-05-04 | 10-Q |
| FY 2023 | 2021-12-31 | -3.99 | 2024-03-21 | 10-K |
| Q3 2022 | 2021-09-30 | -2.71 | 2022-11-03 | 10-Q |
| FY 2022 | 2020-12-31 | -3.09 | 2023-03-21 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.